RegeneCyte (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
This is a two-arm, single-center, single-blind, randomized, placebo-controlled phase IIa
study. A total of 30 subjects with post-COVID will be enrolled.
Biological: RegeneCyte
HPC, Cord Blood
Biological: Placebo
Normal Saline
Inclusion Criteria:
-
1. Male or female aged ≥ 18
-
2. With post-COVID syndrome
-
3. Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or
antigen test)
-
4. Able to provide signed informed consent (by the subject or his/her legally
authorized representative)
-
5. Is willing and able to participate in all aspects of the study, including
completion of subjective evaluations, attendance at scheduled clinic visits,
and compliance with all protocol requirements as evidenced by providing a
written informed consent
Exclusion Criteria:
-
1. Neurological disorders prior to COVID-19 diagnosis
-
2. With pre-existing terminal illness
-
3. With known immune disease
-
4. Is pregnant or breastfeeding
-
5. Is currently participating in another investigational study or has been taking
any other investigational product within the last 4 weeks before screening
-
6. Has received any vaccination within 3 weeks prior to the first IP infusion
-
7. Judged by the investigator to be not suitable for study participation
-
8. Under the conditions that may increase risk of complications based on the
medical judgment of the investigator and the parameters
Myrak Research Center
Miami Lakes, Florida, United States
Not Provided